M

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

DEL Scientist - Platform Chemistry

Translational Research & Bench BiologyPosted on Nov 5
ContractBasel, SwitzerlandCHF90k - CHF105kIn-person

About the Job

Requirements

  • Expertise in DNA-encoded library design, encoding strategies, selection methodologies, and hit triaging.
  • Knowledge of DNA-compatible chemistry and library construction principles.
  • Experience optimizing DNA-encoded library methodologies and workflows.
  • Expertise in next-generation sequencing-based decoding and data interpretation.
  • Understanding of preclinical drug discovery, structure-activity relationship analysis, and hit validation.
  • Experience working with contract research organizations.
  • Familiarity with Spotfire, Prism, SciFinder, Reaxys, and PubMed.
  • Knowledge of orthogonal hit-validation approaches, including surface plasmon resonance/Biacore, fluorescence polarization, enzyme-linked immunosorbent assay, and enzymatic assays.
  • Written and verbal communication skills in English.

Responsibilities

  • Contribute to the design and evolution of next-generation DNA-encoded libraries.
  • Develop innovative encoding, barcoding, and library design strategies.
  • Evaluate novel DNA-compatible chemistries, building blocks, and library architectures.
  • Develop and optimize DNA-encoded library selection methodologies, workflows, and enrichment strategies.
  • Refine next-generation sequencing decoding, hit-calling, and hit-deconvolution approaches in collaboration with the Data Science team.
  • Drive innovation in hit-identification and validation workflows.
  • Collaborate with Biology, Biophysics, and Discovery Chemistry teams to maximize the impact of DNA-encoded libraries.
  • Serve as a scientific partner for DNA-encoded library-focused contract research organization collaborations.

Desired Qualifications

  • Experience in DNA-encoded library technology.
  • Publications, patents, or demonstrated innovation in DNA-encoded library technology.
  • Interest in emerging DNA-encoded library modalities and next-generation screening technologies.

About the Company

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.

Company size
201-500
Company stage
IPO
Headquarters
Boston, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Monte Rosa Therapeutics

See more jobs